HeartBeam Inc. (NASDAQ: BEAT) has received a new U.S. patent that expands the capabilities of its credit card-sized, cable-free ECG device to include acoustic sensing and thoracic impedance measurement. This innovation allows the device to function as a digital stethoscope and assess fluid accumulation in the chest, supporting future applications in structural heart disease and heart failure monitoring. The patent strengthens HeartBeam’s intellectual property portfolio and advances its strategy of developing a multi-modal ambulatory cardiac sensing platform.
The patent adds capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company stated that this development underscores its commitment to transforming cardiac care by providing actionable heart intelligence outside of medical facilities. With this patent, HeartBeam expands its global patent portfolio to 26 issued patents, covering signal acquisition, ECG synthesis algorithms, diagnostic applications, and device hardware.
HeartBeam’s platform technology is designed for portable devices that can collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The new patent builds on this foundation, enabling the device to monitor additional cardiac conditions without altering its existing form factor.
The integration of acoustic sensing and thoracic impedance measurement represents a significant step forward in ambulatory cardiac monitoring. By allowing the device to detect fluid buildup in the lungs and listen to heart sounds, it could facilitate earlier intervention for heart failure patients and those with structural heart disease. This is particularly important given that heart failure affects millions worldwide and often requires frequent monitoring to prevent hospitalizations.
For more details, the full press release is available at https://ibn.fm/jgVf0. Updated information about HeartBeam can be found in the company’s newsroom at https://ibn.fm/BEAT. The cleared indications for use of the HeartBeam System are detailed at https://www.heartbeam.com/indications.
